α‐fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response
Authors:
- 3 December 2015
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (5) , 1001-1008
Abstract
Background and Aims: Eradicating chronic hepatitis C virus (HCV) infection improves liver fibrosis and reduces hepatocellular carcinoma (HCC) incidence in chronic HCV patients. We evaluated the relationship between fibrosis regression, as assessed by sequential biopsies, and clinical factors of patients with sustained virological response (SVR). Methods: We retrospectively enrolled 130 patients (74 men; 60.1 ± 8.1 years) with chronic HCV treated with interferon and ribavirin therapy who achieved SVR. To evaluate the change in fibrosis stage over time, all patients underwent a pre‐therapy initial biopsy and a second biopsy after achieving SVR. Results: The mean time between biopsies was 5.5 ± 1.2 years. Fibrosis stage regressed in 55 patients (42.3%), remained stable in 69 (53.1%), and progressed in 6 (4.6%). The mean fibrosis stage significantly decreased, from 2.01 ± 0.99 units to 1.61 ± 1.24 units (P < 0.001). Aspartate aminotransferase, γ‐glutamyltransferase, and α‐fetoprotein (AFP) levels at 24 weeks after the end of treatment (EOT) were significantly lower, and the platelet count at 24 weeks after the EOT was significantly higher in patients with fibrosis regression than in those without. Logistic regression analysis confirmed that lower AFP levels (< 5.4 ng/mL) at 24 weeks after the EOT (odds ratio [OR], 4.626; 95% confidence interval [CI], 1.557–13.153; P = 0.006) and HCV genotype 2 (OR, 2.198; 95% CI, 1.010–4.786; P = 0.047) were significant independent predictive factors for regressed fibrosis after SVR. Conclusions: Lower post‐treatment AFP levels and HCV genotype 2 significantly correlated with liver fibrosis regression after SVR.Keywords
This publication has 26 references indexed in Scilit:
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1New England Journal of Medicine, 2012
- Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapyJournal of Medical Virology, 2011
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapyHepatology, 2009
- Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapyJournal of Gastroenterology and Hepatology, 2005
- Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferonJournal of Gastroenterology, 2005
- Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapyLiver International, 2004
- Effect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis Type C: A Long–Term Observation Study of 1,643 Patients Using Statistical Bias Correction With Proportional Hazard AnalysisHepatology, 1999
- Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis CHepatology, 1998
- Epidemiology of Hepatitis C in the WestSeminars in Liver Disease, 1995
- Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis CHepatology, 1994